Disease Overview：Lung Cancer Screening（LC (ESD)）
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Early-stage disease—defined as Stage I or II, where tumors are localized and have not metastasized to distant organs—offers the best prognosis, with five-year survival rates exceeding 60–90% following curative-intent intervention. However, early detection is challenging due to nonspecific symptoms such as persistent cough or mild dyspnea; thus, low-dose computed tomography (LDCT) screening is recommended for high-risk individuals, including long-term smokers and those with occupational exposure or family history. Diagnostic confirmation relies on integrated approaches: bronchoscopy with endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA), image-guided percutaneous biopsy, and molecular profiling (e.g., EGFR, ALK, ROS1 testing) to guide targeted therapy decisions.
China offers distinct advantages in early lung cancer management. Leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital—combine deep expertise in interventional pulmonology with state-of-the-art LDCT protocols, AI-enhanced nodule analysis software, and rapid-turnaround genomic testing. Clinical outcomes align with international benchmarks: over 92% diagnostic accuracy for subcentimeter nodules and median time-to-treatment initiation under 10 days. Crucially, comprehensive early-stage workups—including PET-CT, EBUS, and biomarker assays—cost 40–60% less than equivalent services in the US or Western Europe, without compromising quality or regulatory compliance (NMPA-certified devices, ISO-accredited labs). As a dedicated medical tourism agency, we facilitate seamless access for international patients: pre-arrival coordination with top-tier respiratory institutes, itemized and transparent pricing in advance, visa support, multilingual clinical liaisons, and end-to-end care navigation—from initial teleconsultation through post-procedure follow-up.
Lung Cancer Screening: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Early Lung Cancer Screening & Diagnosis (Respiratory Medicine)
Non-Surgical / Conservative Diagnostic Options
*Indicated for asymptomatic high-risk individuals (e.g., ≥45 years, ≥20 pack-year smoking history, occupational exposure, family history)*
- •Low-Dose Chest CT (LDCT)
- *Fee*: $120–$180 (includes radiologist interpretation, DICOM storage)
- •Sputum Cytology + Biomarker Panel (miR-21, CYFRA 21-1, ProGRP)
- *Fee*: $45–$75 (cytology: $22; biomarker panel: $23–$53)
- •Bronchoscopy with Autofluorescence Imaging (AFI) + Brushing/BAL
- *Fee*: $380–$520 (procedure: $290; AFI module: $65; cytology + molecular testing: $25–$165)
Surgical / Interventional Diagnostic Options
*Indicated for solid/ground-glass nodules ≥6 mm with growth or suspicious features on LDCT*
- •CT-Guided Transthoracic Needle Biopsy (TTNB)
- *Pre-op workup*: CBC, PT/INR, chest X-ray — $35 - *Procedure fee*: $410–$590 (ultrasound/CT guidance, core biopsy kit, pathologist rapid on-site evaluation)
- •Video-Assisted Thoracoscopy Surgery (VATS) Biopsy + Wedge Resection
- *Pre-op workup*: Pulmonary function test, ECG, echocardiogram — $110 - *Procedure fee*: $2,800–$4,100 (VATS suite time, disposable trocars, frozen section, pathology grossing/microscopy)
Special/Complex Condition Options
- •Endobronchial Ultrasound (EBUS)-TBNA for Mediastinal Staging
- *Fee*: $640–$890 (EBUS scope use, needle, cytology + PD-L1/EGFR testing if indicated)
- •Liquid Biopsy (ctDNA NGS Panel)
- *Fee*: $320–$480 (50-gene panel, turnaround 7–10 days)
Quick Selection Guide
- •Age <55, budget-conscious, no comorbidities: Start with LDCT ($120–$180) — highest sensitivity for early adenocarcinoma.
- •Age ≥65, COPD/heart failure, bleeding risk: Prioritize EBUS-TBNA ($640–$890) over TTNB — lower pneumothorax/hemorrhage risk.
- •Solid nodule ≥15 mm, rapid growth: Proceed directly to VATS biopsy ($2,800–$4,100) — diagnostic avoids repeat procedures.
- •Ground-glass opacity (GGO) ≥10 mm, young non-smoker: LDCT + 3-month follow-up preferred; avoid invasive biopsy unless progression — cost: $120 × 2 = $240.
- •Suspected multifocal disease or genetic predisposition: Add **liquid biopsy ($320–$480 to guide surveillance intensity.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Lung Cancer Screening Medical Vacation Packages
Curated transparent all-inclusive packages combining Lung Cancer Screening treatment with China top medical destinations:
